Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS

Cancer, 05/10/2012

RAS mutations in acute myeloid leukemia (AML) may delineate a subset of patients who benefit from AraC–based therapy and who may be amenable to treatment with inhibitors of RAS and PI3K signaling pathways.

Print Article Summary Cat 2 CME Report